Showing results (41-50 of 59) with videos related to
Sort By:
Pageof 6
Experimental Dermatology|June 4, 2021
Target molecules for future hidradenitis suppurativa treatmentChristos C Zouboulis, John W Frew, Evangelos J Giamarellos-Bourboulis, et al.Nature Communications|March 25, 2026
IgA autoantibodies promote inflammation, Th17 polarization and fibrotic responses in hidradenitis suppurativaCarmelo Carmona-Rivera, Liam J O'Neil, Eduardo Patino-Martinez, et al.American Journal of Clinical Dermatology|March 10, 2026
Defining Moderate Disease and Progression in Hidradenitis Suppurativa: An Expert Framework to Unlock the Window of Opportunity for Prompt TreatmentAntonio Martorell, John R Ingram, Christopher J Sayed, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|October 3, 2022
Development and validation of IHS4-55, an IHS4 dichotomous outcome to assess treatment effect for hidradenitis suppurativaThrasivoulos Tzellos, Kelsey R van Straalen, Athanassios Kyrgidis, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|February 14, 2026
Bimekizumab efficacy using IHS4 outcomes in hidradenitis suppurativa: Results from BE HEARD I and IIThrasyvoulos Tzellos, Evangelos J Giamarellos-Bourboulis, Kelsey R van Straalen, et al.Journal of the American Academy of Dermatology|November 17, 2025
Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extensionChristopher J Sayed, Brian Kirby, Amit Garg, et al.Pain and Therapy|October 17, 2025
Bimekizumab Pain Outcomes in Patients with Hidradenitis Suppurativa: Pooled 48-Week Results from BE HEARD I&II Phase 3 Randomized Clinical TrialsJohn R Ingram, Hideki Fujita, Alice B Gottlieb, et al.JAMA Dermatology|July 26, 2023
Genetic Variants Associated With Hidradenitis SuppurativaQuan Sun, K Alaine Broadaway, Sharon N Edmiston, et al.Lancet (London, England)|May 25, 2024
Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trialsAlexa B Kimball, Gregor B E Jemec, Christopher J Sayed, et al.The British Journal of Dermatology|November 17, 2023
Global consensus process to establish a core dataset for hidradenitis suppurativa registriesHannah E Wainman, Nisha S Chandran, John W Frew, et al.Pageof 6